Analgesic, anesthetic, and addiction Clinical Trial translations, innovations, opportunities, and networks

Chemotherapy-induced peripheral neuropathy (CIPN) Trial Design Considerations

PARTICIPANT LIST

Joanna Brell, MD

Clinical Associate Professor of Medicine

MetroHealth Medical Center-Cancer Center

Case Western Reserve University

Cleveland, Ohio

Guido Cavaletti, MD, PhD

Professor

School of Medicince and Surgery

University of Milano-Bicocca

Monza, Italy

James Cleary, MD, PhD

Instructor of Medicine

Dana-Farber Cancer Institute

Harvard Medical School

Boston, Massachusetts

Daniela Dastros-Pitei, MD, PhD

Head of Medical Science, Pain and New Products

Mundipharma Research Limited

Cambridge, United Kingdom

Patrick Dougherty, PhD

Professor, Department of Pain Medicine, Division of Anesthesiology and Critical Care

The University of Texas MD Anderson Cancer Center

Houston, Texas

Robert H. Dworkin, PhD

Professor of Anesthesiology, Neurology, Oncology & Psychiatry

Professor of Neurology in the Center for Human Experimental Therapeutics

University of Rochester School of Medicine and Dentistry

Rochester, New York

Scott Evans, PhD, MS

Senior Research Scientist

Harvard University

Boston, Massachusetts

Roy Freeman, MD

Professor of Neurology

Harvard Medical School

Beth Israel Deaconess Medical Center

Boston, Massachusetts

Ellen Fields, MD, MPH

Deputy Director

Division of Anesthesia, Analgesia, and Addiction Products

FDA/CDER

Silver Spring, Maryland

Lynn Gauthier, PhD

Assistant Professor

Department of Family and Emergency Medicine

Faculty of Medicine, Laval University

Researcher

Québec City, Québec, Canada

Jennifer Gewandter, PhD, MPH

Assistant Professor

University of Rochester School of Medicine and Dentistry

Rochester, New York

Simon Haroutounian, MSc Pharm, PhD

Assistant Professor

Department of Anesthesiology

Washington University School of Medicine

Washington University Pain Center

St. Louis, Missouri

Sharon Hertz, MD

Division Director

Division of Anesthesia, Analgesics and Addiction Products

DAAAP/CDER/FDA

Silver Spring, Maryland

Pamela Horn, MD

Clinical Reviewer

FDA

Silver Spring, Maryland

Lynn Howie, MD

Medical Officer

FDA

Silver Spring, Maryland

Ning Hu, MD

Medical Officer

CDER/OND/DAAAP

FDA

Silver Spring, Maryland

Matthew Jarpe, PhD

Associate VP Biology

Regenacy Pharmaceuticals

Boston, Massachusetts

Nathaniel Katz, MD, MS

CEO Analgesic Solutions

Adjunct Associate Professor

Tufts University

Boston, Massachusetts

Allison Lin, PharmD, PhD

Associate Director for Special Projects

Division of Anesthesia, Analgesia, and Addiction Products

Office of New Drugs

FDA

Silver Spring, Maryland

Joshua Lloyd, MD

Lead Medical Officer

FDA

Silver Spring, Maryland

Charles Loprinzi, MD

Regis Professor of Breast Cancer Research

Medical Oncologist

Mayo Clinic

Rochester, Minnesota

Michael McDermott, PhD

Professor of Biostatistics and Neurology

University of Rochester Medical Center

Rochester, New York

Ann O’Mara, PhD, RN

Program Director and Head

Palliative Care Research

Division of Cancer Prevention

Community Oncology and Prevention Trials Research Group

National Cancer Institute

National Institutes of Health

Bethesda, Maryland

Elektra Papadoulos, MD, MPH

Medical Lead; Study Endpoints Team

OND/CDER

FDA

Silver Spring, Maryland

Paul Richardson, MD

Clinical Program Leader

Director of Clinical Research

Dana-Farber Cancer Institute

Boston, Massachusetts

A. Gordon Smith, MD, FAAN

Professor, Neurology

University of Utah

Salt Lake City, Utah

Ellen Lavoie Smith, PhD, APRN, AOCN®, FAAN

Associate Professor

University of Michigan School of Nursing

Ann Arbor, Michigan

Patrick Wen, MD

Director of Neuro-Oncology

Dana-Farber Cancer Institute

Boston, Massachusetts

Lisa Wiltrout, MD

Medical Officer

FDA

Silver Spring, Maryland

Yan Zhou, PhD

Senior Staff Fellow

FDA

Silver Spring, Maryland